CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily Practice Through Educational Approach)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00681122
First received: May 20, 2008
Last updated: October 13, 2011
Last verified: October 2011
  Purpose

This observational study is restricted to postmenopausal women with hormone-sensitive early breast cancer, who have decided to take prescribed adjuvant use of AIs, anastrozole or letrozole, according to the current product SmPCs. There is no Investigational Medicinal Product (IMP) to be taken in this observational study. The adjuvant AI medication must not have exceeded thirteen weeks. In CARIATIDE (Compliance of ARomatase Inhibitors AssessmenT In Daily practicE through Educational approach), impact of educational material on women's compliance and persistence rates will be evaluated.


Condition
Breast Cancer

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: An International, Observational Study to Evaluate the Impact of Educational Material on the Compliance and Persistence Rates to Adjuvant Aromatase Inhibitor (AI) Medication for Postmenopausal Woman

Resource links provided by NLM:


Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • The compliance rate for the adjuvant AI medication will be analysed at one year based on the subject's assessment. [ Time Frame: once after one year ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Persistence rate will be evaluated for the first time after one year and a second time after two years. The Investigator will ask the subject about her persistence as follows: [ Time Frame: After one and two years. ] [ Designated as safety issue: No ]
  • Time to treatment discontinuation is defined as number of days between the date of first and last intake of AI medication. Dates for AI treatment start and discontinuation will be documented in the CRF. [ Time Frame: After one and two years ] [ Designated as safety issue: No ]
  • Reasons for discontinuation of AI: recurrence, death, physician's recommendation, interactions with other medication, side effects, treatment with other hormone medication than anastrozole or letrozole, unfilled AI prescription, subject's wish, other. [ Time Frame: After one and two years ] [ Designated as safety issue: No ]

Estimated Enrollment: 2600
Study Start Date: May 2008
Study Completion Date: May 2011
Primary Completion Date: May 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
1
Standard therapy
2
Standard therapy + educational material

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Probability Sample
Study Population

Postmenopausal women with hormone sensitive early breast cancer that have been prescribed adjuvant AI medication (aromatase inhibitors; anastrozole or letrozole) according to the current product SmPC. The adjuvant AI medication must not have exceeded thirteen weeks of treatment duration.

Criteria

Inclusion Criteria:

  • Postmenopausal woman with hormone sensitive early breast cancer
  • Documented decision of treatment with upfront adjuvant AI (either anastrozole or letrozole) according to current SmPC OR current treatment with AI (either anastrozole or letrozole) according to current SmPC, that has not exceeded thirteen weeks

Exclusion Criteria:

  • Upfront adjuvant AI medication which has exceeded thirteen weeks at randomisation
  • Concomitant adjuvant treatment with tamoxifen or exemestane
  • Previous use of adjuvant tamoxifen or exemestane exceeding thirteen weeks
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00681122

  Hide Study Locations
Locations
Australia, Australian Capital Territory
Research Site
Canberra, Australian Capital Territory, Australia
Australia, New South Wales
Research Site
Coffs Harbour, New South Wales, Australia
Research Site
Newcastle, New South Wales, Australia
Research Site
Port Macquarie, New South Wales, Australia
Research Site
Tweed Heads, New South Wales, Australia
Australia, Queensland
Research Site
Brisbane, Queensland, Australia
Research Site
Nambour, Queensland, Australia
Research Site
Toowoomba, Queensland, Australia
Australia, Tasmania
Research Site
Hobart, Tasmania, Australia
Austria
Research Site
St. Veit, Carinthia, Austria
Research Site
Wolfsberg, Carinthia, Austria
Research Site
Weiz, Styria, Austria
Research Site
Linz, Upper Austria, Austria
Research Site
V�klabruck, Upper Austria, Austria
Research Site
Salzburg, Austria
Research Site
Vienna, Austria
Belgium
Research Site
Aalst, Belgium
Research Site
Antwerpen, Belgium
Research Site
Arlon, Belgium
Research Site
Bonheiden, Belgium
Research Site
Bornem, Belgium
Research Site
Boussu, Belgium
Research Site
Brussels, Belgium
Research Site
Charleroi, Belgium
Research Site
Dendermonde, Belgium
Research Site
Edegem, Belgium
Research Site
Eupen, Belgium
Research Site
Geel, Belgium
Research Site
Gent, Belgium
Research Site
Geraardsbergen, Belgium
Research Site
Gilly, Belgium
Research Site
Haine St Paul, Belgium
Research Site
Leuven, Belgium
Research Site
Li?ge, Belgium
Research Site
Libramont, Belgium
Research Site
Namur, Belgium
Research Site
Oostende, Belgium
Research Site
Ottignies, Belgium
Research Site
Overpelt, Belgium
Research Site
Rocourt, Belgium
Research Site
Seraing, Belgium
Research Site
Tournai, Belgium
Research Site
Turnhout, Belgium
Chile
Research Site
Santiago, Metropolitana, Chile
Research Site
Temuco, Novena Region, Chile
Colombia
Research Site
Medellin, Antioquia, Colombia
Research Site
Barranquilla, Atlantico, Colombia
Research Site
Bogota, Cundinamarca, Colombia
Research Site
Neiva, Huila, Colombia
Research Site
Pasto, Nari?o, Colombia
Research Site
Cali, Valle, Colombia
Croatia
Research Site
Osijek, Croatia
Research Site
Rijeka, Croatia
Research Site
Zagreb, Croatia
Czech Republic
Research Site
Hradec Kralove, Czech Republic
Research Site
Opava, Czech Republic
Research Site
Ostrava, Czech Republic
Research Site
Praha, Czech Republic
Finland
Research Site
Helsinki, Finland
Research Site
Tampere, Finland
France
Research Site
Aix En Provence, France
Research Site
Ales, France
Research Site
Annecy, France
Research Site
Arpajon, France
Research Site
Avignon, France
Research Site
Beauvais, France
Research Site
Bordeaux, France
Research Site
Brest, France
Research Site
Brive La Gaillarde, France
Research Site
Colmar, France
Research Site
Creteil, France
Research Site
Cucq, France
Research Site
Dechy, France
Research Site
Evreux, France
Research Site
GAP, France
Research Site
Grenoble, France
Research Site
Hyeres, France
Research Site
La Seyne Sur Mer, France
Research Site
Limoges, France
Research Site
Lyon, France
Research Site
Mareuil Les Meaux, France
Research Site
Marseille, France
Research Site
Mont de Marsan, France
Research Site
Mougins, France
Research Site
Nancy, France
Research Site
Nantes, France
Research Site
Narbonne, France
Research Site
Nice, France
Research Site
Nimes, France
Research Site
Perigueux, France
Research Site
Perpignan, France
Research Site
Quimper, France
Research Site
Reims, France
Research Site
Rennes, France
Research Site
Rouen, France
Research Site
Saint Brieux, France
Research Site
Saint Cyr Sur Loire, France
Research Site
Saint Gregoire, France
Research Site
Saint Jean, France
Research Site
Saint Mande, France
Research Site
Saint Nazaire, France
Research Site
Strasbourg, France
Research Site
Thonon Les Bains, France
Research Site
Toulon, France
Research Site
Toulouse, France
Research Site
Valence, France
Research Site
Vannes, France
Research Site
Villeneuve Sur Lot, France
Greece
Research Site
Patras, Achaia, Greece
Research Site
Athens, Greece
Research Site
Piraeous, Greece
Research Site
Thessaloniki, Greece
Research Site
Trikala, Greece
Italy
Research Site
Lido di Camaiore, Lucca, Italy
Research Site
Bologna, Italy
Research Site
Cosenza, Italy
Research Site
Pavia, Italy
Research Site
Roma, Italy
Research Site
Treviso, Italy
Peru
Research Site
Lima, Peru
Research Site
Piura, Peru
Romania
Research Site
Alba-Iulia, Romania
Research Site
Baia Mare, Romania
Research Site
Bucuresti, Romania
Research Site
Cluj-Napoca, Romania
Research Site
Oradea, Romania
Research Site
Suceava, Romania
Sweden
Research Site
G�teborg, Sweden
Research Site
Karlskrona, Sweden
Research Site
Link�ping, Sweden
Research Site
Skellefte?, Sweden
Research Site
Sk�vde, Sweden
Research Site
Stockholm, Sweden
Switzerland
Research Site
Baden, Switzerland
Research Site
Bern, Switzerland
Research Site
Lugano, Switzerland
Research Site
St. Gallen, Switzerland
Research Site
Zurich, Switzerland
Turkey
Research Site
Ankara, Turkey
Research Site
Diyarbakir, Turkey
Research Site
Eskisehir, Turkey
Research Site
Gaziantep, Turkey
Research Site
Istanbul, Turkey
Research Site
Izmir, Turkey
Research Site
Kayseri, Turkey
Research Site
Konya, Turkey
Research Site
Malatya, Turkey
Research Site
Mersin, Turkey
United Kingdom
Research Site
St Albans, Hertfordshire, United Kingdom
Research Site
Brighton, United Kingdom
Research Site
Bristol, United Kingdom
Research Site
Cardiff, United Kingdom
Research Site
Cheltenham, United Kingdom
Research Site
Coventry, United Kingdom
Research Site
Dundee, United Kingdom
Research Site
Edinburgh, United Kingdom
Research Site
Glasgow, United Kingdom
Research Site
Liverpool, United Kingdom
Research Site
London, United Kingdom
Research Site
Macclesfield, United Kingdom
Research Site
Manchester, United Kingdom
Research Site
Northwood, United Kingdom
Research Site
Nottingham, United Kingdom
Research Site
Scarborough, United Kingdom
Research Site
Shrewsbury, United Kingdom
Research Site
York, United Kingdom
Venezuela
Research Site
Caracas, Distrito Capital, Venezuela
Research Site
Valencia, Estado Carabobo, Venezuela
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Neven, P. Prof. KUL
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT00681122     History of Changes
Other Study ID Numbers: NIS-OEU-ARI-2007/1
Study First Received: May 20, 2008
Last Updated: October 13, 2011
Health Authority: Austria: Ethikkommission
Czech Republic: Ethics Committee
Czech Republic: State Institute for Drug Control
France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Finland: Ethics Committee
Finland: Ministry of Social Affairs and Health
Finland: Finnish Medicines Agency
Greece: Ethics Committee
Greece: Ministry of Health and Welfare
Greece: National Organization of Medicines
Italy: Ethics Committee
Romania: National Medicines Agency
Sweden: Regional Ethical Review Board
Switzerland: Ethikkommission
Turkey: Ministry of Health
United Kingdom: Research Ethics Committee

Keywords provided by AstraZeneca:
Breast Cancer
hormone therapy
aromatase inhibitor

Additional relevant MeSH terms:
Breast Neoplasms
Neoplasms by Site
Neoplasms
Breast Diseases
Skin Diseases
Aromatase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions

ClinicalTrials.gov processed this record on April 15, 2014